logo
Plus   Neg
Share
Email

Retrophin: Phase 3 FORT Study Fails To Meet Endpoints - Quick Facts

Retrophin, Inc. (RTRX), a biopharmaceutical company, said the Phase 3 Study evaluating fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration failed to meet primary endpoint, as well as secondary endpoint. Fosmetpantotenate was generally safe and well-tolerated in the study.

Retrophin said the company will discuss with study investigators to decide the next steps for the FORT Study, including the ongoing open-label extension of the study.

Retrophin said it remains focused on advancing two pivotal Phase 3 programs evaluating sparsentan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
RELATED NEWS
Follow RTT
>